Abstract
Inherited cardiac conditions (ICCs) can lead to sudden cardiac death at any age, yet are often asymptomatic and clinically undetected. Prophylactic interventions are available and cascade testing is recommended to identify family members at risk. When a disease-causing mutation has been identified in a family, pre-symptomatic genetic testing (PSGT) is available. This study explores perceptions of the cascade process, impact of PSGT and attitudes towards direct contact as an alternative to family-mediated dissemination for ICCs. In depth, interviews were conducted with 22 participants eligible for PSGT for Hypertrophic Cardiomyopathy or Long QT syndrome. Data were analysed using an inductive, thematic approach. Risk is perceived to be low pre-test in the absence of symptoms, and participants frequently test with the aim of ruling out risk to self and children. Testing of children is a complex decision; although older participants have concerns about possible adverse effects of genetic testing early in the life course, young participants are pragmatic about their result. The meaning of a positive genetic test result may be difficult to conceptualise in the absence of clinical evidence of disease, and this may deter further dissemination to at-risk family members. A majority of participants see advantages in direct contact from health professionals and support it in principle. Implications for practice include addressing risk perception pre-test, and presenting genetic test information as part of a risk stratification process rather than a binary outcome. Families may require more support or intervention in cascading genetic test information.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Goldenberg I, Moss AJ. : Long QT syndrome. J Am Coll Cardiol 2008; 51: 2291–2300.
Watkins H, Ashrafian H, Redwood C : Inherited cardiomyopathies. N Engl J Med 2011; 364: 1643–1656.
Heart Rhythm UK Familial Sudden Death Syndromes Statement Development Group: Clinical indications for genetic testing in familial sudden cardiac death syndromes: an HRUK position statement. Heart 2008; 94: 502–507.
Pelliccia A, Fagard R, Bjørnstad HH et al: Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005; 26: 1422–1445.
Maron BJ. : Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with HCM. Circ J. 2010; 74: 2271–2282.
Wordsworth S, Leal J, Blair E et al: DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J. 2010; 31: 926–935.
Ingles J, McGaughran J, Scuffham PA et al: A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart 2012; 98: 625–630.
Christiaans I, Birnie E, Bonsel GJ et al: Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J. 2011; 32: 1161–1170.
Christiaans I, Birnie E, Bonsel GJ et al: Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy. Eur J Hum Genet 2008; 16: 1201–1207.
Brooks L, Lennard F, Shenton A et al: BRCA1/2 predictive testing: a study of uptake in two centres. Eur J Hum Genet 2004; 12: 654–662.
van der Roest WP, Pennings JM, Bakker M et al: Family letters are an effective way to inform relatives about inherited cardiac disease. Am J Med Genet A. 2009; 149A: 357–363.
Broadstock M, Michie S, Marteau T. : Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000; 8: 731–738.
Heshka JT, Palleschi C, Howley H et al: A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med 2008; 10: 19–32.
Foster C, Watson M, Eeles R et al: Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. Br J Cancer 2007; 96: 718–724.
Ostman-Smith I, Wettrell G, Keeton B et al: Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J. 2008; 29: 1160–1167.
Report on the Genetic Testing of Children, British Society for Human Genetics 2010 http://www.bshg.org.uk/GTOC_Booklet_Final_new.pdf, accessed on 25 June 2012.
Ingles J, Lind JM, Phongsavan P, Semsarian C. : Psychosocial impact of specialized cardiac genetic clinics for HCM. Genet Med 2008; 10: 117–120.
Christiaans I, van Langen IM, Birnie E et al: Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients' perspective. Am J Med Genet A. 2009; 149A: 1444–1451.
Strauss A, Corbin J. : Basics of Qualitative Research Techniques and Procedures for Developing Grounded Theory 2nd edn London: Sage Publications, 1998.
Forrest K, Simpson SA, Wilson BJ et al: To tell or not to tell: barriers and facilitators in family communication about genetic risk. Clin Genet 2003; 64: 317–326.
Ingles J, Yeates L, Hunt L et al: Health status of cardiac genetic disease patients and their at risk relatives. Int J Cardiol 2011, e-pub ahead of print 17 September 2011.
Christiaans I, van Langen IM, Birnie E et al: Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. Am J Med Genet A 2009; 149A: 602–612.
Hunt K, Davison C, Emslie C, Ford G. : Are perceptions of a family history of heart disease related to health-related attitudes and behaviour? Health Educ Res 2000; 15: 131–143.
Geelen E, Van Hoyweghen I, Doevendans PA et al: Constructing ‘best interests’: genetic testing of children in families with hypertrophic cardiomyopathy. Am J Med Genet A 2011; 155A: 1930–1938.
Borry P, Evers-Kiebooms G, Cornel MC et alPublic and Professional Policy Committee (PPPC) of the European Society of Human Genetics (ESHG): Genetic testing in asymptomatic minors: background considerations towards ESHG Recommendations. Eur J Hum Genet 2009; 17: 711–719.
Watkins H, Seidman JG, Seidman E. : Genetic Testing for Hypertrophic Cardiomyopathy. N Engl J Med 1992; 327: 1175–1176.
Hendriks KS, Grosfeld FJ, Wilde AA et al: High distress in parents whose children undergo predictive testing for long QT syndrome. Community Genet 2005; 8: 103–113.
Farnsworth MM, Fosyth D, Haglund C, Ackerman MJ. : When I go in to wake them... I wonder: parental perceptions about congenital long QT syndrome. J Am Acad Nurse Pract 2006; 18: 284–290.
Smets EM, Stam MM, Meulenkamp TM et al: Health-related quality of life of children with a positive carrier status for inherited cardiovascular diseases. Am J Med Genet A. 2008; 146A: 700–707.
Biesecker BB, Erby L : Adaptation to living with a genetic condition or risk: a mini-review. Clin Genet 2008; 74: 401–407.
Taylor S.E. : Adjustment to threatening events: A theory of cognitive adaptation. Am Psychol 1983; 38: 1161–1173.
Suthers GK, Armstrong J, McCormack J, Trott D. : Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. J Med Genet 2006; 43: 665–670.
Hallowell N, Foster C, Eeles R et al: Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information. J Med Ethics 2003; 29: 74–79.
Ormondroyd E, Moynihan C, Ardern-Jones A et al: Communicating genetics research results to families: problems arising when the patient participant is deceased. Psychooncology 2008; 17: 804–811.
van Maarle MC, Stouthard ME, Marang-van de Mheen PJ et al: How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia? Community Genet 2001; 4: 244–252.
Hallowell N, Jenkins N, Douglas M et al: Patients' experiences and views of cascade screening for familial hypercholesterolemia (FH): a qualitative study. J Community Genet 2011; 2: 249–257.
Newson AJ, Humphries SE. : Cascade testing in familial hypercholesterolaemia: how should family members be contacted? Eur J Hum Genet 2005; 13: 401–408.
Acknowledgements
We thank the participants for their time. We are grateful to Kathryn Smith and Eunice Berry for transcribing the interviews. The study was made possible by a grant from the Oxford NIHR Biomedical Research Centre to HW and EB.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ormondroyd, E., Oates, S., Parker, M. et al. Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications. Eur J Hum Genet 22, 88–93 (2014). https://doi.org/10.1038/ejhg.2013.81
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2013.81
Keywords
This article is cited by
-
Direct notification by health professionals of relatives at-risk of genetic conditions (with patient consent): views of the Australian public
European Journal of Human Genetics (2024)
-
Community concerns about genetic discrimination in life insurance persist in Australia: A survey of consumers offered genetic testing
European Journal of Human Genetics (2024)
-
Study protocol: the Australian genetics and life insurance moratorium—monitoring the effectiveness and response (A-GLIMMER) project
BMC Medical Ethics (2021)
-
Barriers and facilitators for cascade testing in genetic conditions: a systematic review
European Journal of Human Genetics (2020)
-
Secondary findings in inherited heart conditions: a genotype-first feasibility study to assess phenotype, behavioural and psychosocial outcomes
European Journal of Human Genetics (2020)
